Article

BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant

2021-03-31

Abstract excerpt

Background: Age is the major risk factor for mortality after SARS-CoV-2 infection and older people have received priority consideration for COVID-19 vaccination. However vaccine responses are often suboptimal in this age group and few people over the age of 80 years were included in vaccine registration trials.<br><br>Methods: We determined the serological and cellular response to spike protein in 100 people aged...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 11470b8b-4319-5349-a52b-112d577043ae
DOI: 10.2139/ssrn.3816840

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian VariantDOI 10.2139/ssrn.3816840Read

Single Vaccination with BNT162b2 or ChAdOx1 in Older People Induces Equivalent Antibody Generation but Enhanced Cellular Responses after ChAdOx1Semantic proximity Read

Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Elderly People Over 85 Years of Age in GreeceSemantic proximity Read

Competent immune responses to SARS-CoV-2 variants in older adults following mRNA vaccinationSemantic proximity Read

T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort StudySemantic proximity Read

COVID-19 mRNA vaccine induced antibody responses and neutralizing antibodies against three SARS-CoV-2 variantsSemantic proximity Read

SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodiesSemantic proximity Read

Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2Semantic proximity Read

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodiesSemantic proximity Read

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responsesSemantic proximity Read

Immunogenicity and Reactogenicity of a First Booster with NT162b2or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1)Semantic proximity Read